PHASE 1/2 TRIAL OF ANTI‐PD‐LIGAND 1 (DURVALUMAB) +/‐ LENALIDOMIDE IN PATIENTS WITH CUTANEOUS T CELL LYMPHOMA: PRELIMINARY RESULTS OF PHASE 1 AND CORRELATIVE STUDIES

Saved in:
Bibliographic Details
Published inHematological oncology Vol. 37; no. S2; pp. 519 - 520
Main Authors Querfeld, C., Zain, J., Jovanovic‐Talisman, T., Wakefield, D.L., Kil, S., Estephan, R., Young, P., Sanchez, J., Martinez, X., Stiller, T., Palmer, J., Rosen, S.T.
Format Journal Article
LanguageEnglish
Published Chichester Wiley Subscription Services, Inc 01.06.2019
Subjects
Correlation analysis
Immunotherapy
Lymphocytes T
Lymphoma
Monoclonal antibodies
T-cell lymphoma
Targeted cancer therapy
Online AccessGet full text

Cover

More Information
ISSN:0278-0232
1099-1069
DOI:10.1002/hon.205_2631